JP5438250B2 - オピオイド及びオピオイド様の化合物並びにそれらの使用 - Google Patents

オピオイド及びオピオイド様の化合物並びにそれらの使用 Download PDF

Info

Publication number
JP5438250B2
JP5438250B2 JP2004505341A JP2004505341A JP5438250B2 JP 5438250 B2 JP5438250 B2 JP 5438250B2 JP 2004505341 A JP2004505341 A JP 2004505341A JP 2004505341 A JP2004505341 A JP 2004505341A JP 5438250 B2 JP5438250 B2 JP 5438250B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
compounds
appendix
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004505341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530798A (ja
JP2005530798A5 (https=
Inventor
イェン，マオ−シュン
ファン，チン−ツァイ
Original Assignee
ジェンケン バイオサイエンスィズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェンケン バイオサイエンスィズ，インコーポレイテッド filed Critical ジェンケン バイオサイエンスィズ，インコーポレイテッド
Publication of JP2005530798A publication Critical patent/JP2005530798A/ja
Publication of JP2005530798A5 publication Critical patent/JP2005530798A5/ja
Application granted granted Critical
Publication of JP5438250B2 publication Critical patent/JP5438250B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
JP2004505341A 2002-05-17 2003-05-16 オピオイド及びオピオイド様の化合物並びにそれらの使用 Expired - Fee Related JP5438250B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38084102P 2002-05-17 2002-05-17
US60/380,841 2002-05-17
PCT/US2003/015461 WO2003097608A2 (en) 2002-05-17 2003-05-16 Opioid and opioid-like compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013228118A Division JP6165592B2 (ja) 2002-05-17 2013-11-01 薬学的な組成物

Publications (3)

Publication Number Publication Date
JP2005530798A JP2005530798A (ja) 2005-10-13
JP2005530798A5 JP2005530798A5 (https=) 2006-06-29
JP5438250B2 true JP5438250B2 (ja) 2014-03-12

Family

ID=29550023

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004505341A Expired - Fee Related JP5438250B2 (ja) 2002-05-17 2003-05-16 オピオイド及びオピオイド様の化合物並びにそれらの使用
JP2013228118A Expired - Fee Related JP6165592B2 (ja) 2002-05-17 2013-11-01 薬学的な組成物
JP2015089558A Expired - Lifetime JP6193298B2 (ja) 2002-05-17 2015-04-24 薬学的な組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013228118A Expired - Fee Related JP6165592B2 (ja) 2002-05-17 2013-11-01 薬学的な組成物
JP2015089558A Expired - Lifetime JP6193298B2 (ja) 2002-05-17 2015-04-24 薬学的な組成物

Country Status (9)

Country Link
EP (2) EP2987788A1 (https=)
JP (3) JP5438250B2 (https=)
CN (2) CN103405431B (https=)
AU (2) AU2003234621A1 (https=)
CA (1) CA2486157C (https=)
HK (1) HK1220452A1 (https=)
MX (1) MXPA04011327A (https=)
TW (1) TWI275591B (https=)
WO (1) WO2003097608A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2521914Y2 (ja) 1988-12-23 1997-01-08 エヌティエヌ株式会社 大型転がり軸受

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20040204862A1 (en) 2003-04-11 2004-10-14 Wainer Irving W. Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors
CA2566445C (en) * 2004-05-12 2016-02-02 The Government Of The United States As Represented By The Secretary, Department Of Health And Human Services Methods related to the treatment of neurodegenerative and inflammatory conditions
AU2005244401B2 (en) 2004-05-14 2009-01-22 Green Cross Corp. Neuroprotective properties of dextrorotatory morphinans
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
FI3825306T3 (fi) 2007-05-01 2023-08-23 Concert Pharmaceuticals Inc Morfinaaniyhdisteitä
EP2183228B1 (en) 2007-07-26 2014-08-20 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CL2008003407A1 (es) 2007-11-16 2010-01-11 Boehringer Ingelheim Int Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
CN102908339A (zh) * 2007-11-23 2013-02-06 格吕伦塔尔有限公司 他喷他多组合物
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8598160B2 (en) 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CL2009001059A1 (es) 2008-05-01 2010-11-12 Boehringer Ingelheim Int Compuestos derivados de 1,3-oxazin-2-ona-3,6 sustituidos, inhibidores de la actividad de la 11-beta-hidroxiesteroide deshidrogenasa i; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades tales como diabetes mellitus, entre otras.
AR071236A1 (es) 2008-05-01 2010-06-02 Vitae Pharmaceuticals Inc Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
WO2009134387A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8765780B2 (en) 2008-05-13 2014-07-01 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
US8846668B2 (en) 2008-07-25 2014-09-30 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2010011314A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
EP2334678B1 (en) 2008-09-19 2012-12-26 Concert Pharmaceuticals Inc. Morphinan compounds
CA2744946A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
AR078887A1 (es) 2009-11-06 2011-12-07 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina y composiciones farmaceuticas que los contienen.
WO2011137734A1 (en) 2010-05-03 2011-11-10 Tsh Biopharm Company, Limited Pharmaceutical composition and method for treating hypertension
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
PH12013500808A1 (en) 2010-11-02 2015-10-07 Boehringer Ingelheim Int Pharmaceutical combinations for the treatment of metabolic disorders
TWI537258B (zh) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
US8987293B2 (en) * 2010-12-23 2015-03-24 Phoenix Pharmalabs, Inc. Morphinans useful as analgesics
JP2014524438A (ja) 2011-08-17 2014-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インデノピリジン誘導体
CN102731399B (zh) * 2012-07-06 2013-11-06 启东东岳药业有限公司 高纯度3-甲氧基-9α,13α,14α吗啡喃盐酸盐的制备方法
CN103254131A (zh) * 2013-04-23 2013-08-21 苏州谷力生物科技有限公司 一种右美沙芬原料药的精制工艺
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
JP6248711B2 (ja) 2014-03-06 2017-12-20 株式会社デンソー 回転電機の固定子
US9757372B2 (en) 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
EP3445363A1 (en) 2016-04-22 2019-02-27 Taiwanj Pharmaceuticals Co., Ltd. Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
EP3565556A4 (en) * 2017-01-05 2020-06-10 Taiwanj Pharmaceuticals Co., Ltd. MORPHINE DERIVATIVES AND COMPOSITIONS THERE FOR TREATING AUTOIMMUNE, INFLAMMATION OR INFECTIOUS DISEASES
CN107157998A (zh) * 2017-05-26 2017-09-15 张灏 右美沙芬的新用途
CA3130708A1 (en) * 2019-02-19 2020-08-27 Robert Barsotti Solutions and methods for organ preservation
CN119977886B (zh) * 2025-02-13 2025-08-22 安徽益普克医药科技发展有限公司 一种葡萄糖酸喷他佐辛苯甲酸酯及其制备方法与用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275638A (en) 1966-09-27 Chjcoo-
NL127995C (https=) 1963-12-20 Geigy Ag J R
GB1038732A (en) 1963-12-31 1966-08-10 Hoffmann La Roche Morphinan derivatives and a process for the manufacture thereof
IE34235B1 (en) 1969-06-04 1975-03-19 Acf Chemiefarma Nv 6,7-benzomorphans and their preparation
CA919668A (en) 1970-06-20 1973-01-23 Murakami Masuo Morphinan derivatives
BE788478A (fr) 1971-09-08 1973-03-06 Bristol Myers Co Procede de preparation de composes analgesiques
DE2238839A1 (de) * 1972-08-07 1974-02-14 Boehringer Sohn Ingelheim Neue morphinon-derivate, deren saeureadditionssalze, verfahren zu ihrer herstellung sowie ihre verwendung zur herstellung von arzneimitteln
DE2259979A1 (de) 1972-12-07 1974-06-12 Bayer Ag Benzomorphan-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JPS514175A (en) * 1974-07-01 1976-01-14 Yamanouchi Pharma Co Ltd Morufuinanjudotaino goseiho
GB1513961A (en) 1975-02-25 1978-06-14 Acf Chemiefarma Nv 6,7-benzomorphans method for their preparation and intermediates
US4029798A (en) 1975-06-02 1977-06-14 Sumitomo Chemical Company, Limited Analgetic composition
GB1575009A (en) 1976-06-21 1980-09-17 Acf Chemiefarma Nv 6,7-benzomorphan derivatives
US4161597A (en) * 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
CA1093070A (en) 1978-02-10 1981-01-06 Michael P. Kotick 8.beta.-ALKYL-SUBSTITUTED MORPHINAN-6-ONE COMPOUNDS
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4267182A (en) * 1979-01-16 1981-05-12 The United States Of America As Represented By The Secretary Of The Army Narcotic antagonists in the therapy of shock
US4228285A (en) 1979-02-28 1980-10-14 Bristol-Myers Company 14-Hydroxy-6-oxamorphinans and 14-hydroxy-6-oxaisomorphinans
US4388463A (en) 1981-07-16 1983-06-14 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services 6-Keto-morphinan analgesics
US4390699A (en) 1981-07-16 1983-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 6-Keto-morphinans belonging to the 14-hydroxy-series
IN163125B (https=) 1985-01-08 1988-08-13 Alkaloida Vegyeszeti Gyar
HU196376B (en) 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
US4673679A (en) 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4912114A (en) 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives
FR2636330B1 (fr) 1988-09-13 1990-11-30 Sanofi Sa Procede de preparation de derives de morphinane
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
GB9103302D0 (en) * 1991-02-16 1991-04-03 Smithkline Beecham Plc Pharmaceutical formulations
US5556857A (en) * 1991-05-08 1996-09-17 Otsuka Pharmaceutical Co., Ltd. Disturbance-of-consciousness improving agent
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
DE4121821A1 (de) 1991-07-02 1993-01-14 Boehringer Ingelheim Kg Neue benzomorphane und ihre verwendung als arzneimittel
US5219347A (en) 1991-12-24 1993-06-15 Laser Engineering, Inc. Decoupled dual-beam control system
KR970011390B1 (ko) 1992-01-23 1997-07-10 도레이 가부시키가이샤 모르피난 유도체와 약리학적으로 허용되는 이의 산 부가염 및 이를 함유하는 약제학적 조성물
US6271239B1 (en) 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5354758A (en) 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
TW264473B (https=) * 1993-01-06 1995-12-01 Hoffmann La Roche
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
AU686203B2 (en) * 1993-07-23 1998-02-05 Toray Industries, Inc. Morphinan derivative and medicinal use
CZ281174B6 (cs) 1993-08-13 1996-07-17 Galena, A.S. Způsob přípravy 3,14ß-dihydroxy-17-normorfinanu
EP0866656B1 (en) * 1995-09-19 2007-04-25 MARGOLIN, Solomon B. Use of n-substituted pyridones as tumor necrosis factor alpha inhibitors
DE19602971A1 (de) 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue 7,8-Dihydromorphinderivate, Verfahren zu deren Herstellung und deren Verwendung
GB9616253D0 (en) * 1996-08-01 1996-09-11 Johnson Matthey Plc Preparation of narcotic analgesics
US5912347A (en) 1996-09-30 1999-06-15 Mallinckrodt Inc. Process for preparing a morphinan derivative
US5780479A (en) 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
JPH1160483A (ja) * 1997-08-25 1999-03-02 Akira Kanematsu Ｔｎｆ産生阻害剤
JPH1160484A (ja) * 1997-08-25 1999-03-02 Akira Kanematsu Ｔｎｆ産生阻害剤
US6166211A (en) * 1999-03-19 2000-12-26 Endo Pharmaceuticals, Inc. Sequential benzylic oxidations of the naloxone ring system
JP2001058957A (ja) * 1999-08-20 2001-03-06 Toray Ind Inc 癌転移抑制剤
AUPQ968300A0 (en) * 2000-08-25 2000-09-21 Glaxo Wellcome Australia Ltd Chemical methods
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2521914Y2 (ja) 1988-12-23 1997-01-08 エヌティエヌ株式会社 大型転がり軸受

Also Published As

Publication number Publication date
CA2486157A1 (en) 2003-11-27
AU2003234621A1 (en) 2003-12-02
JP2005530798A (ja) 2005-10-13
EP1506174B1 (en) 2015-09-30
JP2015155449A (ja) 2015-08-27
HK1192711A1 (zh) 2014-08-29
CN1653050A (zh) 2005-08-10
CN103405431B (zh) 2016-04-13
CN103405431A (zh) 2013-11-27
EP2987788A1 (en) 2016-02-24
JP6165592B2 (ja) 2017-07-19
JP2014043452A (ja) 2014-03-13
AU2010212517A1 (en) 2010-09-16
WO2003097608A2 (en) 2003-11-27
HK1220452A1 (en) 2017-06-09
TW200427690A (en) 2004-12-16
TWI275591B (en) 2007-03-11
JP6193298B2 (ja) 2017-09-06
MXPA04011327A (es) 2005-08-15
CN1653050B (zh) 2013-04-24
EP1506174A2 (en) 2005-02-16
WO2003097608A3 (en) 2004-03-18
CA2486157C (en) 2013-04-16

Similar Documents

Publication Publication Date Title
JP6193298B2 (ja) 薬学的な組成物
US8404706B2 (en) Opioid and opioid-like compounds and uses thereof
CN101827819B (zh) 阿片样物质酰胺季铵盐
JPH0648944A (ja) 経口投与のための鎮痛剤
JP4532109B2 (ja) 新規オリパビン誘導体および医薬としてのその使用
WO2011119605A2 (en) Carboxamide biosiosteres of opiates
JP2002501923A (ja) 治療用化合物
EP1736157B1 (en) Morphinan derivatives as anti-itching agent
US9776971B2 (en) Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) Opioid and opioid-like compounds and uses thereof
DE69628543T2 (de) Indolderivate und ihre medizinische verwendung
TWI430992B (zh) 類鴉片及類似之類鴉片化合物及其用途（二）
HK1192711B (en) Opioid and opioid-like compounds and uses thereof
US4477456A (en) Octahydro-4A,7-ethano- and -etheno-benzofuro[3,2-e]isoquinoline derivatives having analgesic, narcotic antagonist and anorexigenic properties
JPWO2001014382A1 (ja) モルヒナン４級アンモニウム塩誘導体を有効成分とする鎮痛薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101019

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20101112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131016

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131213

R150 Certificate of patent or registration of utility model

Ref document number: 5438250

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees